rindopepimut
Trade name: Rintega
Vaccineexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00458601)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1VACCINE ANTIGEN
Epidermal growth factor receptor erbB1 vaccine antigen
Cancer vaccine
Targets the EGFRvIII mutation site
- Epidermal growth factor receptor erbB1Immunity, active
EGFR immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107863 ↗
Also known as
- alt110
- alt 110
- alt-110
- cdx110
- cdx 110
- cdx-110
- cdx-110
- pf04948568
- pf 04948568
- pf-04948568
- pf-04948568
- pf4948568
- pf 4948568
- pf-4948568
- rindopepimut
- rindopepimut
- rindopepimut
- rindopepimut
- rintega
- spx110
- spx 110
- spx-110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03068650 | N/A | Feb 27, 2017 | Celldex Therapeutics |
| NCT01498328 | Phase 2 | Dec 1, 2011 | Celldex Therapeutics |
| NCT01480479 | Phase 3 | Nov 1, 2011 | Celldex Therapeutics |
| NCT01058850 | Phase 1 | Jun 1, 2011 | National Cancer Institute (NCI), National Institutes of Health (NIH), Stanford University |
| NCT00458601 | Phase 2 | Aug 1, 2007 | Celldex Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 4 | 4 | 3 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1